查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1776226

血栓清除装置:市场洞察·竞争情形·市场预测 (～2032年)

Thrombectomy Devices - Market Insights, Competitive Landscape, and Market Forecast - 2032
出版日期: | 出版商: DelveInsight | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

预计血栓清除器械市场规模将从2024年的16.5688亿美元增长至2032年的28.0685亿美元，预测期内复合年增长率为6.83%。

血栓清除器械的需求受多个关键因素驱动，支撑了市场的强劲成长。首先，全球神经系统和心血管疾病（例如急性缺血性中风、肺栓塞和深部静脉血栓形成 (DVT)）的发生率不断上升，需要快速有效的干预。此外，患者和医护人员也越来越多地选择微创治疗。领先企业的持续创新和新产品的推出，进一步推动了市场的成长，他们加大对先进技术的投入，以开发能够提高手术效率和疗效的下一代产品。这些趋势共同为市场在2025年至2032年期间的持续成长奠定了有利基础。

血栓切除器械：市场动态

根据英国心臟基金会（2024年）的报告，全球约有5600万女性和4500万男性中风，这表明脑血管疾病在全球范围内造成了沉重的负担。该基金会的另一份报告（截至2022年）也估计，全球冠状动脉疾病的患病人数将达到约2.5亿人，这进一步凸显了有效干预措施的必要性。此外，世界中风组织（2023年）的数据估计，四分之一的25岁及以上成年人在其一生中会经历中风，全球已有超过1.1亿人经历过中风。血栓清除装置在物理清除阻塞动脉和静脉的血栓，恢復急性缺血性中风和周边动脉血栓形成等危及生命的疾病中的血流方面发挥着至关重要的作用。

根据澳洲国家健康研究所 (2022) 的数据，澳洲每年有超过 17,000 人患有静脉血栓栓塞症 (VTE)。血栓相关疾病的增加进一步凸显了对血栓清除装置等有效治疗方法的需求。

此外，英国心臟基金会 (2025) 的最新数据估计，到 2024 年，英国将有超过 760 万人患有心臟病或循环系统疾病，其中包括 400 万男性和 360 万名女性。预计到2030年，这一数字将增加100万，到2040年将再增加200万，这将推动对治疗这些慢性疾病的先进医疗技术的需求，尤其是能够快速清除血栓并恢復血液流动的设备。

此外，美国心臟协会（2023年）报告称，週边动脉疾病（PAD）影响着美国超过1200万人和全球超过2亿人。 PAD病例的快速增长推动了对血栓清除设备的需求，这些设备广泛用于清除心臟和脑外动脉的阻塞。这些微创设备在恢復血液流动、缓解症状和改善长期疗效方面发挥关键作用。

本报告研究了全球血栓清除设备市场，并提供了市场概况、市场影响因素和机会分析、监管环境、市场规模趋势和预测、按细分市场、地区和主要国家/地区进行的详细分析、竞争格局以及主要公司的概况。

目录

第1章 血栓清除装置市场报告:简介

  • 调查范围
  • 市场区隔
  • 市场估计

第2章 血栓清除装置市场:摘要整理

  • 市场概要

第3章 竞争情形

第4章 法规分析

  • 美国
  • 欧洲
  • 日本
  • 中国

第5章 血栓清除装置市场:主要要素分析

  • 推动市场要素
    • 增长神经系统与心血管疾病
    • 微创和非手术治疗需求不断增长
    • 主要公司产品开发活动不断增加
  • 市场限制与课题
    • 血栓切除术相关风险与併发症
    • 严格的监管审批和合规要求
  • 市场机遇
    • 机器人手术和人工智慧引导手术等先进技术的发展
    • 溶栓药物与血栓切除器械的整合

第6章 血栓清除装置市场:波特的五力分析

第7章 血栓清除装置市场评估

  • 各产品
    • 吸引血栓清除装置
    • 超音波血栓清除装置
    • 其他
  • 各用途
    • 末稍血管血栓消除术
    • 冠状动脉血栓消除术
    • 神经血管血栓消除术
  • 各终端用户
    • 医院·诊疗所
    • 门诊病人手术中心
  • 地区
    • 北美
    • 欧洲
    • 亚太地区
    • 其他地区

第8章 血栓清除装置市场:企业·产品简介

  • Stryker
  • Abbott Laboratories
  • Boston Scientific Corporation
  • Argon Medical Devices
  • Contego Medical, Inc.
  • Mermaid Medical
  • Surmodics, Inc.
  • Penumbra, Inc.
  • Medtronic
  • Johnson & Johnson Services, Inc.
  • Edwards Lifesciences Corporation
  • Terumo Corporation
  • Koninklijke Philips N.V.
  • MicroPort Scientific Corporation
  • Thrombolex
  • phenox GmbH
  • Acandis GmbH
  • Inova
  • Vesalio Inc.
  • ZYLOX-TONBRIDGE MEDICAL TECHNOLOGY CO., LTD.

第9章 KOL的见解

第10章 计划方法

第11章 关于DelveInsight

第12章 询问免责声明

Product Code: DIMDCL0692

Thrombectomy Devices Market by Product (Mechanical Thrombectomy Devices, Aspiration Thrombectomy Devices, Ultrasonic Thrombectomy Devices, and Others), Application (Peripheral Vascular Thrombectomy, Coronary Vascular Thrombectomy, and Neurovascular Thrombectomy), End-User (Hospitals & Clinics, Ambulatory Surgical Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2032 owing to the growing prevalence of neurological and cardiovascular diseases and increasing product development activities among the key market players.

The thrombectomy devices market was valued at USD 1,656.88 million in 2024, growing at a CAGR of 6.83% during the forecast period from 2025 to 2032 to reach USD 2,806.85 million by 2032. The growing demand for thrombectomy devices is driven by several key factors supporting strong market growth. The rising global prevalence of neurological and cardiovascular conditions such as acute ischemic stroke, pulmonary embolism, and deep vein thrombosis, among others necessitate timely, effective interventions. Additionally, there is a clear shift toward minimally invasive treatment options, preferred by both patients and healthcare providers. Further fueling growth in the market is the continuous innovation and product launches by leading players, which are investing in advanced technologies and launching next-generation products that enhance procedural efficiency and outcomes. Collectively, these trends are creating a favorable environment for sustained market expansion from 2025 to 2032.

Thrombectomy Devices Market Dynamics:

According to the British Heart Foundation (2024), an estimated 56 million women and 45 million men worldwide were stroke survivors, reflecting the immense global burden of cerebrovascular disease. The same source also reported that, as of 2022, nearly 250 million people globally were living with coronary heart disease, further emphasizing the need for effective interventional solutions. Similarly, data from the World Stroke Organization (2023), highlighted that one in four adults over the age of 25 would suffer a stroke in their lifetime, and over 110 million individuals worldwide had already experienced one. Thrombectomy devices play a vital role in restoring blood flow by physically removing blood clots that obstruct arteries or veins, especially in acute, life-threatening conditions such as ischemic stroke or peripheral arterial thrombosis.

According to data from the National Institute of Health (2022), over 17,000 individuals in Australia develop venous thromboembolism (VTE) annually. This rising burden of blood clot-related conditions underscores the critical need for effective treatment options like thrombectomy devices.

Recent data from the British Heart Foundation (2025) revealed that, in 2024, more than 7.6 million people in the UK were living with heart and circulatory diseases, including over 4 million men and 3.6 million women with projections indicating that this number was expected to grow by 1 million by 2030, and by 2 million by 2040, highlighting the increasing demand for advanced medical technologies to manage these conditions, particularly devices that can promptly remove dangerous clots and restore blood flow.

Moreover, data from the American Heart Association (2023), reported that more than 12 million Americans, along with 200 million individuals globally, were suffering from peripheral artery disease (PAD). This alarming rise in PAD cases is fueling demand for thrombectomy devices, which are widely used to clear blockages in arteries outside the heart and brain. These minimally invasive devices play a crucial role in restoring circulation, alleviating symptoms, and improving long-term patient outcomes.

Further, key market players are intensifying their R&D efforts to develop and commercialize next-generation thrombectomy systems. For instance, in March 2025, Inari Medical (part of Stryker) launched the Artix(TM) Thrombectomy System, an integrated platform combining aspiration and mechanical thrombectomy for peripheral arterial disease. This next-generation device offers enhanced procedural control and versatility, expanding treatment options for patients with arterial thromboembolic conditions.

In April 2024, AngioDynamics received FDA clearance for its AlphaVac F1885 System to treat pulmonary embolism (PE), expanding its use beyond general thrombectomy. This minimally invasive device offers a mechanical solution for removing blood clots, improving clinical outcomes and safety for PE patients. The clearance, supported by strong clinical trial results, is expected to drive market growth by broadening treatment options and enhancing procedural efficiency.

However, the risk and complications associated with thrombectomy procedures and the strict regulatory approvals and compliance requirements, among others are some of the key constraints that may limit the growth of the thrombectomy devices market.

Thrombectomy Devices Market Segment Analysis:

Thrombectomy Devices Market by Product (Mechanical Thrombectomy Devices, Aspiration Thrombectomy Devices, Ultrasonic Thrombectomy Devices, and Others), Application (Peripheral Vascular Thrombectomy, Coronary Vascular Thrombectomy, and Neurovascular Thrombectomy), End-User (Hospitals & Clinics, Ambulatory Surgical Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the product segment of the thrombectomy devices market, the mechanical thrombectomy devices category is estimated to account for the largest market share in 2024. This can be primarily attributed to the rising prevalence of cardiovascular disorders (CVDs) such as strokes. Additionally, various advantages and applications provided by these devices could also raise the demand for the category.

A major factor driving this segment is the rising global prevalence of peripheral vascular and thrombotic disorders, such as peripheral artery disease (PAD), stroke, deep vein thrombosis (DVT), and pulmonary embolism (PE). According to the British Heart Foundation (2024), over 110 million individuals were affected by peripheral arterial (vascular) disease, while 94 million people globally were living with the effects of stroke. Similarly, the Global Stroke Factsheet (2022), stated that the risk of developing a stroke has increased by 50% over the last 17 years and now 1 in 4 people is estimated to have a stroke in their lifetime. According to the same source, globally 101 million people were suffering from stroke. Thus, the increasing prevalence of CVDs will create a need for the treatment of such disorders leading to the increasing demand for mechanical thrombectomy devices. These figures highlight the urgent need for effective clot-removal solutions often performed by mechanical thrombectomy devices.

One of the key clinical benefits of mechanical thrombectomy is its ability to rapidly restore blood flow, a feature that is especially crucial in life-threatening conditions such as acute ischemic stroke. The minimally invasive design of these devices typically introduced through a small puncture site offers several patient-centric advantages, including shorter hospital stays, quicker return to function, and lower complication rates when compared to open surgery.

Mechanical thrombectomy devices are specialized tools designed to remove blood clots from blood vessels. These devices are primarily used in treating conditions like ischemic stroke, deep vein thrombosis (DVT), and peripheral artery disease. These devices can quickly remove clots, restoring blood flow to affected areas and reducing the risk of long-term damage. In cases of ischemic stroke, this can be crucial in minimizing neurological deficits.

Additionally, by directly targeting and removing the clot, mechanical thrombectomy can reduce the risk of secondary complications like distal embolization (where parts of the clot break off and cause further blockages) and reocclusion (where the vessel becomes blocked again). Further, thrombectomy devices offer precise control over clot removal, which can be particularly advantageous in complex cases where other methods might be less effective or more risky.

Furthermore, various companies are conducting research and development related to thrombectomy devices to increase their product portfolio. For instance, in May 2023, Akura Medical, a Shifamed portfolio company initiated its first-in-human clinical study of the Akura mechanical thrombectomy device. The Akura platform is a low-profile solution designed to easily access and efficiently remove large volume, mixed morphology clots, and eliminate the guesswork around the procedure. Similarly, in April 2025, Surmodics announced the commercial launch of the Pounce(TM) XL Thrombectomy System. This next-generation device was designed for the rapid, non-surgical extraction of acute or chronic clots from the iliac and femoral arteries, eliminating the need for thrombolytic drugs. Such advancements address the critical need for safer, more efficient clot removal options, particularly for patients who are not suitable for thrombolytic therapy.

Thus, the factors mentioned above are likely to boost the market segment and thereby increase the overall market of thrombectomy devices across the globe.

North America is expected to dominate the overall thrombectomy devices market:

North America is expected to hold the largest share of the thrombectomy devices market in 2024, driven by several key factors. The region's dominance can be attributed to the high prevalence of neurovascular, peripheral, and coronary vascular diseases, the rapidly growing geriatric population, and the continuous innovation and product launches by leading medical device companies based in the region. These elements, combined with advanced healthcare infrastructure, favorable reimbursement policies, and increasing awareness of minimally invasive procedures, are expected to sustain North America's leading position in the global market.

According to data from the Centers for Disease Control and Prevention (2024), over 795,000 individuals in the United States experience a stroke each year. Notably, nearly 185,000 of these strokes, accounting for approximately 1 in 4 cases occur in individuals with a history of prior strokes. Additionally, the CDC reported that approximately 900,000 people in the U.S. were affected by venous thromboembolism (VTE) annually, further underlining the substantial burden of thromboembolic diseases. These increasing figures highlighted the growing need for thrombectomy devices, which are designed to physically remove blood clots and restore normal circulation in affected vessels thereby escalating the overall market across the region.

The prevalence of coronary heart disease (CHD) is also a major driver of market growth. According to CDC data from June 2024, around 20.5 million Americans were living with CHD as of 2022. Furthermore, an estimated 6.5 million individuals aged 40 and older were diagnosed with peripheral artery disease (PAD) in the same year. These increasing figures highlight the growing need for thrombectomy devices, which are designed to physically remove blood clots and restore normal circulation in affected vessels.

In addition to rising disease prevalence, North America market is also benefiting from technological innovation and new product launches. For instance, in September 2024, Vesalio announced the U.S. commercialization of the pVasc(TM) Thrombectomy System, a device designed for the non-surgical removal of peripheral occlusions. The pVasc(TM) system targets a wide range of emboli, from soft, acute clots to fibrin-rich, calcified ones, providing a fast, safe, and versatile treatment option. Such developments not only enhance treatment efficacy but also expand the range of conditions that can be managed with thrombectomy devices.

Thrombectomy Devices Market Key Players:

Some of the key market players operating in the thrombectomy devices market include Stryker, Abbott Laboratories, Boston Scientific Corporation, Argon Medical Devices, Contego Medical, Inc., Mermaid Medical, Surmodics, Inc., Penumbra, Inc., Medtronic, Johnson & Johnson Services, Inc., Edwards Lifesciences Corporation, Terumo Corporation, Koninklijke Philips N.V., MicroPort Scientific Corporation, Thrombolex, phenox GmbH, Acandis GmbH, Inova, Vesalio Inc., ZYLOX-TONBRIDGE MEDICAL TECHNOLOGY CO., LTD., and others.

Recent Developmental Activities in the Thrombectomy Devices Market:

  • In February 2025, Stryker completed the acquisition of Inari Medical, Inc., significantly strengthening its position in the thrombectomy market. Inari's product portfolio, including the FlowTriever(R) System for pulmonary embolism and the ClotTriever(R) System for peripheral vessel thrombectomy, is highly complementary to Stryker's existing Neurovascular business.
  • In February 2025, the Tendvia(TM) Pulmonary Artery Thrombectomy System from Shanghai Tendfo Medical Device Co., Ltd. received approval from the China National Medical Products Administration (NMPA). The device is indicated for transcatheter thrombectomy in patients with acute high-risk or intermediate-risk pulmonary embolism, offering a minimally invasive treatment option for these critical conditions.
  • In September 2024, Argon Medical Devices announced the launch of the CLEANER Vac(TM) Thrombectomy System, specifically designed for the removal of blood clots from the peripheral venous vasculature. This disposable, large-bore aspiration system was engineered to quickly and effectively remove thrombus (blood clots) from vessels with restricted blood flow.
  • In January 2023, phenox Inc. announced that it had received FDA 510(k) clearance for its pRESET(R) Thrombectomy Device for the treatment of acute ischemic stroke. The pRESET(R) device is used as a mechanical thrombectomy solution designed to restore blood flow in patients experiencing acute ischemic stroke.

Key takeaways from the thrombectomy devices market report study

  • Market size analysis for current thrombectomy devices market size (2024), and market forecast for 8 years (2025 to 2032).
  • Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
  • Key companies dominating the thrombectomy devices market.
  • Various opportunities available for the other competitors in the thrombectomy devices market space.
  • What are the top-performing segments in 2024? How these segments will perform in 2032?
  • Which are the top-performing regions and countries in the current thrombectomy devices market scenario?
  • Which are the regions and countries where companies should have concentrated on opportunities for thrombectomy devices market growth in the coming future?

Target audience who can benefit from this thrombectomy devices market report study

  • Thrombectomy device product providers
  • Research organizations and consulting companies
  • Thrombectomy devices-related organizations, associations, forums, and other alliances
  • Government and corporate offices
  • Start-up companies, venture capitalists, and private equity firms
  • Distributors and traders dealing in thrombectomy devices
  • Various end-users who want to know more about the thrombectomy devices market and the latest technological developments in the thrombectomy devices market.

Frequently Asked Questions for the Thrombectomy Devices Market:

1. What are thrombectomy devices?

  • Thrombectomy devices are medical devices used to remove blood clots from blood vessels, restoring normal blood flow. They are commonly used in treating conditions like stroke, deep vein thrombosis (DVT), and peripheral artery disease (PAD). These devices can be mechanical, aspiration-based, or combined with thrombolytic therapy for enhanced clot removal.

2. What is the market for thrombectomy devices?

  • The thrombectomy devices market was valued at USD 1,656.88 million in 2024, growing at a CAGR of 6.83% during the forecast period from 2025 to 2032 to reach USD 2,806.85 million by 2032.

3. What are the drivers for the thrombectomy devices market?

  • The growing demand for thrombectomy devices is driven by several key factors supporting strong market growth. The rising global prevalence of neurological and cardiovascular conditions such as acute ischemic stroke, pulmonary embolism, and deep vein thrombosis, among others necessitate timely, effective interventions. Additionally, there is a clear shift toward minimally invasive treatment options, preferred by both patients and healthcare providers. Further fueling growth is continuous innovation and product launches by leading players, which are investing in advanced technologies and launching next-generation products that enhance procedural efficiency and outcomes. Collectively, these trends are creating a favorable environment for sustained market expansion from 2025 to 2032.

4. Who are the key players operating in the thrombectomy devices market?

  • Some of the key market players operating in the thrombectomy devices market include Stryker, Abbott Laboratories, Boston Scientific Corporation, Argon Medical Devices, Contego Medical, Inc., Mermaid Medical, Surmodics, Inc., Penumbra, Inc., Medtronic, Johnson & Johnson Services, Inc., Edwards Lifesciences Corporation, Terumo Corporation, Koninklijke Philips N.V., MicroPort Scientific Corporation, Thrombolex, phenox GmbH, Acandis GmbH, Inova, Vesalio Inc., ZYLOX-TONBRIDGE MEDICAL TECHNOLOGY CO., LTD., and others.

5. Which region has the highest share in the thrombectomy devices market?

  • North America is expected to hold the largest share of the thrombectomy devices market in 2024, driven by several key factors. The region's dominance can be attributed to the high prevalence of neurovascular, peripheral, and coronary vascular diseases, the rapidly growing geriatric population, and the continuous innovation and product launches by leading medical device companies based in the region. These elements, combined with advanced healthcare infrastructure, favorable reimbursement policies, and increasing awareness of minimally invasive procedures, are expected to sustain North America's leading position in the global market.

Table of Contents

1. Thrombectomy Devices Market Report Introduction

  • 1.1. Scope of the Study
  • 1.2. Market Segmentation
  • 1.3. Market Assumption

2. Thrombectomy Devices Market Executive Summary

  • 2.1. Market at Glance

3. Competitive Landscape

4. Regulatory Analysis

  • 4.1. The United States
  • 4.2. Europe
  • 4.3. Japan
  • 4.4. China

5. Thrombectomy Devices Market Key Factors Analysis

  • 5.1. Thrombectomy Devices Market Drivers
    • 5.1.1. The growing prevalence of neurological and cardiovascular diseases
    • 5.1.2. Increasing demand for minimally invasive & non-surgical procedures
    • 5.1.3. Increasing product development activities among the key players
  • 5.2. Thrombectomy Devices Market Restraints and Challenges
    • 5.2.1. Risk and complications associated with thrombectomy procedures
    • 5.2.2. Strict regulatory approvals and compliance requirements
  • 5.3. Thrombectomy Devices Market Opportunity
    • 5.3.1. Development of advanced technologies such as robotic surgery, AI-guided surgical procedures, among others
    • 5.3.2. Integration of thrombolytic drugs with thrombectomy devices

6. Thrombectomy Devices Market Porter's Five Forces Analysis

  • 6.1. Bargaining Power of Suppliers
  • 6.2. Bargaining Power of Consumers
  • 6.3. Threat of New Entrants
  • 6.4. Threat of Substitutes
  • 6.5. Competitive Rivalry

7. Thrombectomy Devices Market Assessment

  • 7.1. By Product
    • 7.1.1. Thrombectomy Devices
    • 7.1.2. Aspiration Thrombectomy Devices
    • 7.1.3. Ultrasonic Thrombectomy Devices
    • 7.1.4. Others
  • 7.2. By Application
    • 7.2.1. Peripheral Vascular Thrombectomy
    • 7.2.2. Coronary Vascular Thrombectomy
    • 7.2.3. Neurovascular Thrombectomy
  • 7.3. By End-User
    • 7.3.1. Hospitals & Clinics
    • 7.3.2. Ambulatory Surgical Centers
    • 7.3.3. Others
  • 7.4. By Geography
    • 7.4.1. North America
      • 7.4.1.1. United States Thrombectomy Devices Market Size in USD million (2022-2032)
      • 7.4.1.2. Canada Thrombectomy Devices Market Size in USD million (2022-2032)
      • 7.4.1.3. Mexico Thrombectomy Devices Market Size in USD million (2022-2032)
    • 7.4.2. Europe
      • 7.4.2.1. France Thrombectomy Devices Market Size in USD million (2022-2032)
      • 7.4.2.2. Germany Thrombectomy Devices Market Size in USD million (2022-2032)
      • 7.4.2.3. United Kingdom Thrombectomy Devices Market Size in USD million (2022-2032)
      • 7.4.2.4. Italy Thrombectomy Devices Market Size in USD million (2022-2032)
      • 7.4.2.5. Spain Thrombectomy Devices Market Size in USD million (2022-2032)
      • 7.4.2.6. Rest of Europe Thrombectomy Devices Market Size in USD million (2022-2032)
    • 7.4.3. Asia-Pacific
      • 7.4.3.1. China Thrombectomy Devices Market Size in USD million (2022-2032)
      • 7.4.3.2. Japan Thrombectomy Devices Market Size in USD million (2022-2032)
      • 7.4.3.3. India Thrombectomy Devices Market Size in USD million (2022-2032)
      • 7.4.3.4. Australia Thrombectomy Devices Market Size in USD million (2022-2032)
      • 7.4.3.5. South Korea Thrombectomy Devices Market Size in USD million (2022-2032)
      • 7.4.3.6. Rest of Asia-Pacific Thrombectomy Devices Market Size in USD million (2022-2032)
    • 7.4.4. Rest of the World (RoW)
      • 7.4.4.1. Middle East Thrombectomy Devices Market Size in USD million (2022-2032)
      • 7.4.4.2. Africa Thrombectomy Devices Market Size in USD million (2022-2032)
      • 7.4.4.3. South America Thrombectomy Devices Market Size In USD Million (2022-2032)

8. Thrombectomy Devices Market Company and Product Profiles

  • 8.1. Stryker
    • 8.1.1. Company Overview
    • 8.1.2. Company Snapshot
    • 8.1.3. Financial Overview
    • 8.1.4. Product Listing
    • 8.1.5. Entropy
  • 8.2. Abbott Laboratories
    • 8.2.1. Company Overview
    • 8.2.2. Company Snapshot
    • 8.2.3. Financial Overview
    • 8.2.4. Product Listing
    • 8.2.5. Entropy
  • 8.3. Boston Scientific Corporation
    • 8.3.1. Company Overview
    • 8.3.2. Company Snapshot
    • 8.3.3. Financial Overview
    • 8.3.4. Product Listing
    • 8.3.5. Entropy
  • 8.4. Argon Medical Devices
    • 8.4.1. Company Overview
    • 8.4.2. Company Snapshot
    • 8.4.3. Financial Overview
    • 8.4.4. Product Listing
    • 8.4.5. Entropy
  • 8.5. Contego Medical, Inc.
    • 8.5.1. Company Overview
    • 8.5.2. Company Snapshot
    • 8.5.3. Financial Overview
    • 8.5.4. Product Listing
    • 8.5.5. Entropy
  • 8.6. Mermaid Medical
    • 8.6.1. Company Overview
    • 8.6.2. Company Snapshot
    • 8.6.3. Financial Overview
    • 8.6.4. Product Listing
    • 8.6.5. Entropy
  • 8.7. Surmodics, Inc.
    • 8.7.1. Company Overview
    • 8.7.2. Company Snapshot
    • 8.7.3. Financial Overview
    • 8.7.4. Product Listing
    • 8.7.5. Entropy
  • 8.8. Penumbra, Inc.
    • 8.8.1. Company Overview
    • 8.8.2. Company Snapshot
    • 8.8.3. Financial Overview
    • 8.8.4. Product Listing
    • 8.8.5. Entropy
  • 8.9. Medtronic
    • 8.9.1. Company Overview
    • 8.9.2. Company Snapshot
    • 8.9.3. Financial Overview
    • 8.9.4. Product Listing
    • 8.9.5. Entropy
  • 8.10. Johnson & Johnson Services, Inc.
    • 8.10.1. Company Overview
    • 8.10.2. Company Snapshot
    • 8.10.3. Financial Overview
    • 8.10.4. Product Listing
    • 8.10.5. Entropy
  • 8.11. Edwards Lifesciences Corporation
    • 8.11.1. Company Overview
    • 8.11.2. Company Snapshot
    • 8.11.3. Financial Overview
    • 8.11.4. Product Listing
    • 8.11.5. Entropy
  • 8.12. Terumo Corporation
    • 8.12.1. Company Overview
    • 8.12.2. Company Snapshot
    • 8.12.3. Financial Overview
    • 8.12.4. Product Listing
    • 8.12.5. Entropy
  • 8.13. Koninklijke Philips N.V.
    • 8.13.1. Company Overview
    • 8.13.2. Company Snapshot
    • 8.13.3. Financial Overview
    • 8.13.4. Product Listing
    • 8.13.5. Entropy
  • 8.14. MicroPort Scientific Corporation
    • 8.14.1. Company Overview
    • 8.14.2. Company Snapshot
    • 8.14.3. Financial Overview
    • 8.14.4. Product Listing
    • 8.14.5. Entropy
  • 8.15. Thrombolex
    • 8.15.1. Company Overview
    • 8.15.2. Company Snapshot
    • 8.15.3. Financial Overview
    • 8.15.4. Product Listing
    • 8.15.5. Entropy
  • 8.16. phenox GmbH
    • 8.16.1. Company Overview
    • 8.16.2. Company Snapshot
    • 8.16.3. Financial Overview
    • 8.16.4. Product Listing
    • 8.16.5. Entropy
  • 8.17. Acandis GmbH
    • 8.17.1. Company Overview
    • 8.17.2. Company Snapshot
    • 8.17.3. Financial Overview
    • 8.17.4. Product Listing
    • 8.17.5. Entropy
  • 8.18. Inova
    • 8.18.1. Company Overview
    • 8.18.2. Company Snapshot
    • 8.18.3. Financial Overview
    • 8.18.4. Product Listing
    • 8.18.5. Entropy
  • 8.19. Vesalio Inc.
    • 8.19.1. Company Overview
    • 8.19.2. Company Snapshot
    • 8.19.3. Financial Overview
    • 8.19.4. Product Listing
    • 8.19.5. Entropy
  • 8.20. ZYLOX-TONBRIDGE MEDICAL TECHNOLOGY CO., LTD.
    • 8.20.1. Company Overview
    • 8.20.2. Company Snapshot
    • 8.20.3. Financial Overview
    • 8.20.4. Product Listing
    • 8.20.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us

List of Tables

  • Table 1: Competitive Analysis
  • Table 2: Thrombectomy Devices Market in Global (2022-2032)
  • Table 3: Thrombectomy Devices Market in Global by Product (2022-2032)
  • Table 4: Thrombectomy Devices Market in Global by Application (2022-2032)
  • Table 5: Thrombectomy Devices Market in Global by End-User (2022-2032)
  • Table 6: Thrombectomy Devices Market in Global by Geography (2022-2032)
  • Table 7: Thrombectomy Devices Market in North America (2022-2032)
  • Table 8: Thrombectomy Devices Market in the United States (2022-2032)
  • Table 9: Thrombectomy Devices Market in Canada (2022-2032)
  • Table 10: Thrombectomy Devices Market in Mexico (2022-2032)
  • Table 11: Thrombectomy Devices Market in Europe (2022-2032)
  • Table 12: Thrombectomy Devices Market in France (2022-2032)
  • Table 13: Thrombectomy Devices Market in Germany (2022-2032)
  • Table 14: Thrombectomy Devices Market in United Kingdom (2022-2032)
  • Table 15: Thrombectomy Devices Market in Italy (2022-2032)
  • Table 16: Thrombectomy Devices Market in Spain (2022-2032)
  • Table 17: Thrombectomy Devices Market in the Rest of Europe (2022-2032)
  • Table 18: Thrombectomy Devices Market in Asia-Pacific (2022-2032)
  • Table 19: Thrombectomy Devices Market in China (2022-2032)
  • Table 20: Thrombectomy Devices Market in Japan (2022-2032)
  • Table 21: Thrombectomy Devices Market in India (2022-2032)
  • Table 22: Thrombectomy Devices Market in Australia (2022-2032)
  • Table 23: Thrombectomy Devices Market in South Korea (2022-2032)
  • Table 24: Thrombectomy Devices Market in Rest of Asia-Pacific (2022-2032)
  • Table 25: Thrombectomy Devices Market in the Rest of the World (2022-2032)
  • Table 26: Thrombectomy Devices Market in the Middle East (2022-2032)
  • Table 27: Thrombectomy Devices Market in Africa (2022-2032)
  • Table 28: Thrombectomy Devices Market in South America (2022-2032)

List of Figures

  • Figure 1: Competitive Analysis
  • Figure 2: Thrombectomy Devices Market in Global (2022-2032)
  • Figure 3: Thrombectomy Devices Market in Global by Product (2022-2032)
  • Figure 4: Thrombectomy Devices Market in Global by Application (2022-2032)
  • Figure 5: Thrombectomy Devices Market in Global by End-User (2022-2032)
  • Figure 6: Thrombectomy Devices Market in Global by Geography (2022-2032)
  • Figure 7: Thrombectomy Devices Market in North America (2022-2032)
  • Figure 8: Thrombectomy Devices Market in the United States (2022-2032)
  • Figure 9: Thrombectomy Devices Market in Canada (2022-2032)
  • Figure 10: Thrombectomy Devices Market in Mexico (2022-2032)
  • Figure 11: Thrombectomy Devices Market in Europe (2022-2032)
  • Figure 12: Thrombectomy Devices Market in France (2022-2032)
  • Figure 13: Thrombectomy Devices Market in Germany (2022-2032)
  • Figure 14: Thrombectomy Devices Market in United Kingdom (2022-2032)
  • Figure 15: Thrombectomy Devices Market in Italy (2022-2032)
  • Figure 16: Thrombectomy Devices Market in Spain (2022-2032)
  • Figure 17: Thrombectomy Devices Market in the Rest of Europe (2022-2032)
  • Figure 18: Thrombectomy Devices Market in Asia-Pacific (2022-2032)
  • Figure 19: Thrombectomy Devices Market in China (2022-2032)
  • Figure 20: Thrombectomy Devices Market in Japan (2022-2032)
  • Figure 21: Thrombectomy Devices Market in India (2022-2032)
  • Figure 22: Thrombectomy Devices Market in Australia (2022-2032)
  • Figure 23: Thrombectomy Devices Market in South Korea (2022-2032)
  • Figure 24: Thrombectomy Devices Market in Rest of Asia-Pacific (2022-2032)
  • Figure 25: Thrombectomy Devices Market in the Rest of the World (2022-2032)
  • Figure 26: Thrombectomy Devices Market in the Middle East (2022-2032)
  • Figure 27: Thrombectomy Devices Market in Africa (2022-2032)
  • Figure 28: Thrombectomy Devices Market in South America (2022-2032)
  • Figure 29: Market Drivers
  • Figure 30: Market Barriers
  • Figure 31: Marker Opportunities
  • Figure 32: PORTER'S Five Force Analysis